Published in final edited form as:

Pharmacoepidemiol Drug Saf. 2019 March ; 28(3): 305–314. doi:10.1002/pds.4704.

Changing predictors of statin initiation in U.S. women over two decades

Tracy L. Kinsey¹ [MSPH], Til Stürmer¹ [MD, PhD], Charles Poole¹ [ScD], Kenneth J. Rothman² [DrPH], Robert J. Glynn³ [PhD, ScD]

¹Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC

²RTI Health Solutions, Research Triangle Park, NC

³Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA

Abstract

Purpose: To describe changing roles of predictors of statin initiation before and after incident coronary heart disease, and before and after publication of National Cholesterol Education Program Adult Treatment Panel-III (ATP-III) guidelines in a cohort of U.S. women.

Methods: We identified 34,382 women enrolled into the Women's Health Study from 1993–95 and followed until 2012. Proportions of previous non-users initiating statins were described over time. We used multivariable linear regression models to estimate adjusted initiation proportion differences (IPDs) for initiation overall, separately before and after incident coronary heart disease, and separately for ATP-II and ATP-III time periods.

Results: Key predictors of initiation overall were self-reported total cholesterol, and previous incident coronary heart disease, cerebrovascular disease, and diabetes. Adjusted IPDs (percentage) for total cholesterol >240 vs. <200 mg/dl were 7.5 (95% CI, 7.0–8.0) and 9.3 (95% CI, 8.7–9.9) during ATP-II and ATP-III time periods, respectively. Adjusted IPDs in women with diabetes were 7.0 (95% CI, 6.3–7.8) and 11.9 (95% CI, 6.7–17.0) for primary and secondary prevention,

Corresponding author: Tracy L. Kinsey, Doctoral Candidate, Dept. of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 2101 McGovern Greenberg Hall, CB# 7435, Chapel Hill, NC 27599-7435, tkinsey@unc.edu, telephone: 706-207-7544.

ETHICS STATEMENT

The study conforms with the ethical standards of the 1964 Declaration of Helsinki and its later amendments, and U.S. Federal Policy for the Protection of Human Subjects. Free and informed written consent of participants was obtained. The Partners Healthcare and University of North Carolina Institutional Review Boards approved the current study.

CONFLICT OF INTEREST STATEMENT

The authors disclose the following financial relationships and potential conflicts of interest: Tracy Kinsey receives salary from Athens Orthopedic Clinic Foundation for work supported by grants from Stryker and Arthrex. Til Stürmer receives salary support from the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB, Merck) and research grants (Amgen, AstraZeneca) to the Department of Epidemiology, University of North Carolina; he also holds stock in Novartis, Roche, BASF, AstraZeneca, and Novo Nordisk. Charles Poole has received salary support from the Center for Pharmacoepidemiology. Kenneth Rothman is an employee of the Research Triangle Institute, a non-profit organization that does work for government agencies and private companies. Robert Glynn has received research grants (AstraZeneca, Kowa, Pfizer, and Novartis) to the Brigham & Women's Hospital.

Prior presentations: Some material from this work was previously presented at the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.

respectively, and 3.1 (95% CI, 2.1–4.0) and 9.2 (95% CI 8.2–10.2) for before and after ATP-III, respectively.

Conclusions: Secular trends reflected evolution toward risk factor-based treatment indications for statin initiation with increased initiation among diabetics and women with normal and borderline cholesterol. The role of serum cholesterol changed over time, though the character was scale (multiplicative vs. additive) dependent. In pharmacoepidemiologic studies of statins, strength of confounding by important variables sometimes unmeasured in claims data, such as cholesterol level, may be calendar time dependent.

Keywords

pharmacoepidemiology; drugs; utilization; prevention; hyperlipidemia

1. INTRODUCTION

In the early 1990s, the Scandinavian Simvastatin Survival Study demonstrated that statins reduced mortality by 30% in patients with evidence of cardiovascular disease and high cholesterol.¹ Subsequent studies demonstrated benefits for patients with cardiovascular disease and normal cholesterol levels,^{2,3} and for people at high risk of cardiovascular disease regardless of cholesterol level.^{4,5} The National Cholesterol Education Program Adult Treatment Panel (ATP) has provided recommendations for treatment of hypercholesterolemia in the U.S. since 1988.⁶ Updated first in 1993 (ATP-II),⁷ the second update in 2001 (ATP-III) notably expanded use among people without prior cardiovascular disease, diabetics, and older individuals.^{8,9} Male sex, ages 55–75 yrs, higher serum cholesterol, diabetes, cardiovascular disease, antihypertensive medication use, and increased healthcare encounters are known predictors of statin initiation.^{10,11} However, whether predictors change with evolving guidelines or before versus after incident coronary heart disease has been incompletely described.^{12–15} Understanding predictors sometimes not captured in claims data (e.g., cholesterol level) is important in pharmacoepidemiologic studies of statins.

We therefore sought to describe the changing roles of predictors of statin initiation in a cohort of U.S. women before and after incident coronary heart disease, and before and after the ATP III guidelines in 2001.

2. METHODS

2.1 Data source

The Women's Health Study (WHS) is a randomized controlled trial of low-dose aspirin, vitamin E, and beta-carotene for the primary prevention of cardiovascular disease and cancer in U.S. women.^{16–18} From 1993 to 1995, 39,876 female health professionals aged 45 yrs (Table 1) were randomly assigned to a regimen of aspirin (100mg every other day) or placebo and Vitamin E (600 IU every other day) or placebo in a 2 × 2 factorial design. The trial also initially included a beta-carotene component, which was discontinued after 2 years median treatment duration.¹⁹ Participants were followed annually through the scheduled end of the trial (March 31, 2004) and annually thereafter in a program of post-trial observational

follow-up. Data were collected via written questionnaires that participants returned by mail. Details are described elsewhere.^{20,21} Our study includes eligible questionnaires from all WHS participants from enrollment through 7 years post-trial.

2.2 Statin use

Questions regarding current use of cholesterol lowering medications were included in 13 of 20 questionnaires administered during the study period: before randomization (baseline); 12, 36, 48, 108, and 120 months following randomization; at trial conclusion in 2004; and 1, 2, 3, 4, 5, and 7 years after trial conclusion for participants (~90%) of the observational follow-up phase (Appendix, Table S1).

2.3 Predictor variables

We examined statin initiation over time as a function of a set of core covariates available in the WHS. All covariates were measured before randomization, and updated whenever possible. Race, education, and parental history of myocardial infarction before age 60 years²² were collected once at baseline. Age was calculated at every questionnaire. Body mass index (BMI), smoking (current, previous but not current, or never), physical exercise, alcohol use, multivitamin use, menopausal status (pre-menopausal, post-menopausal, or uncertain), hormone replacement therapy use (current, previous, never), and self-reported total blood cholesterol were reassessed only on some questionnaires according to the study design. For these variables, the last recorded value was carried forward to later questionnaires where unmeasured or missing, unless described otherwise. Missing baseline values remained missing until updated by a recorded value on a later questionnaire, after which the new value was carried forward until updated again. Missing values were not imputed with later values except for baseline height, which was imputed with values from later questionnaires if available. BMI was calculated from self-reported height and weight and carried forward by linear interpolation when unreported. Self-reported weight was highly correlated with measured weight ($r=0.97$) among similar women in the Nurses' Health Study.²³ Menopausal status was imputed to post-menopausal for all women at ages 60 years in the absence of self-report data indicating otherwise.²⁴ Physical exercise was classified as < 7.5, 7.5–21, and >21 met-hours per week.²⁵ 7.5 met-hours represents the minimum physical activity for adults recommended by Federal guidelines.²⁶ Women reported their total serum cholesterol at baseline, if known within 5 years, and were asked for updated values if known 12 and 36 months post-randomization, at trial conclusion, and 1, 3, 5, and 7 years post-trial. 6,273 WHS participants (16%) had unknown or missing total cholesterol at study entry.²⁷ Total cholesterol was classified as <200 mg/dl (low risk), 200–239 mg/dl (moderate risk), and 240+ mg/dl (high risk).^{7,8} Data were not consistently available for low density lipoprotein (LDL) cholesterol. A validation study of the WHS cohort showed self-reported baseline total cholesterol values were 9.7 mg/dl (95% CI, 9.2, 10.2) higher on average than values obtained from baseline blood samples, but were strongly associated with incident cardiovascular disease during follow-up.²⁷

Women were queried yearly regarding cardiovascular disease events and new diagnoses of diabetes and hypertension. Incident cardiovascular disease, a primary trial endpoint, underwent medical records verification by an endpoint committee of physician reviewers.¹⁸

We only counted confirmed events. Confirmed myocardial infarction, angina, coronary artery bypass surgery, or percutaneous coronary angioplasty were combined into a single endpoint for coronary heart disease. Confirmed stroke, transient ischemic attack, or carotid endarterectomy surgery were combined into a single cerebrovascular disease endpoint. Self-reported diabetes diagnoses were followed up with a supplemental validated questionnaire.²⁸ Hypertension was defined as a self-reported diagnosis, self-reported antihypertensive medication use, or self-reported systolic blood pressure ≥ 140 or diastolic ≥ 90 mmHg. Dates of first lifetime incidence were identified for coronary heart disease, cerebrovascular disease, diabetes, and hypertension.

2.4 Study design

We defined statin initiation as the first instance of reported use.^{10,29} A woman reporting no use of statins on her first questionnaire was classified as a non-initiator for that questionnaire and became eligible to initiate on the next questionnaire, and so on; if she reported statin use, she was classified as an initiator and became ineligible to initiate thereafter. Each woman's follow-up time was thereby conceptualized as a sequence of discrete observations, each consisting of an inter-questionnaire period during which the woman was eligible to initiate ('eligibility period') culminating in the questionnaire where she indicated her current use or non-use of statins. The up-to-date covariate values on first day of the eligibility period were used as the predictors for initiation on that questionnaire. Because statin use was asked at irregular intervals, the lengths of eligibility periods varied from 1 to 5 years. We restricted the analysis to questionnaires with eligibility period length < 27 months to limit variation of person-time between the discrete observations. This cut point would capture questionnaires scheduled 2 years apart allowing a 3 months grace period for late returns. Sensitivity analyses were performed without this restriction. 225,757 questionnaires of 34,382 women were included in the analysis (Figure 1).

2.5 Analytic methods

Distributions of covariates were described cross-sectionally among women who contributed scheduled questionnaires at 12 months post-randomization, trial conclusion, and 7 years post-trial. Statin initiation was characterized as crude incidence rates overall and by levels of covariates across 4-year time periods. Each day of person-time during the eligibility period was classified by calendar year period. When initiation occurred, dates of initiation were imputed as the midpoint of the eligibility period and person-days afterward omitted from calculations. We estimated initiation incidence rates (IRs) per 100 person-years with 95% confidence intervals (CIs) for each time period and incidence rate differences (IRDs) with 95% CIs comparing the latest time period with the earliest.

We used multivariable linear regression with empirical variance estimation to predict the non-recurring binary outcome of statin initiation as a function of the covariates and to estimate initiation proportion differences (IPDs), expressed as percentages, with 95% CIs for the independent contribution of covariates on statin initiation.^{30,31} The unit of analysis was the questionnaire. Women could contribute multiple questionnaires to the pooled analysis, but each woman could only initiate once.³² Models were constructed overall, separately for questionnaires with and without a first lifetime incidence of coronary heart disease before

the eligibility period, and separately for questionnaires with eligibility periods wholly contained before, and on or after May 16, 2001 (ATP-III guidelines publication date).⁸ Models included terms for calendar year of questionnaire return. Logistic regression models were constructed using identical variables to estimate odds ratios (ORs) with 95% CIs for comparison with the additive models. Terms for interaction by incident coronary heart disease before the eligibility period and time period (ATP-II vs. ATP-III) were tested using score tests for linear regression or likelihood ratio tests for logistic regression after fitting respective full interaction models. Additive interactions of previous incident coronary heart disease and time period (ATP-II vs. ATP-III) with selected ordinal and continuous covariates were described by estimating relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (SI) with 95% confidence intervals after binary reclassification of the covariate.^{33,34} We quantified residual confounding bias during ATP-II versus ATP-III time periods under a scenario of confounding of the association of statin initiation and cardiovascular disease outcomes by total cholesterol level using methods described elsewhere by Schneeweiss, et. al.³⁵ We used bivariate proportions of initiation and elevated total cholesterol from the WHS, and literature-based relative risks of elevated total cholesterol on incident cardiovascular disease among middle-aged women from the Framingham risk score prediction model.³⁶ SAS 9.3 software (SAS Institute, Cary, NC) was used for all analyses.

3. RESULTS

3.1 Trends and predictors of statin initiation

Prevalent use of statins among all 39,876 WHS participants was 3% at baseline and 43% in 2011; of 38,608 baseline non-users, 17,451 (45%) initiated some time during follow-up. Covariate distributions of included women over the study period are shown on Table 2.

Crude incidence of initiation was characterized by a sharp peak during 2001–04 (IR per 100 person-years 8.1 [95% CI, 7.8–8.4], up from 1.6 [95% CI, 1.5–1.7] during 1993–96) followed by sequential decline to approximately half the peak rate in 2009–2012 (IR 3.8 [95% CI, 3.6–4.0]); this general pattern was mirrored within most covariate substrata, including age, suggesting that changes in statin initiation could not be attributed to aging in this fixed cohort (Figure 2; Appendix, Table S2).

In the full multivariable model, the absolute initiation proportion (%) increased over calendar time until stabilizing during 2005–08 and 2009–12 at approximately 4.5 percentage points greater than 1993–96 (adjusted IPDs 4.3 [95% CI, 4.0–4.6] and 4.6 [95% CI, 4.2–4.9], respectively) (Appendix, Table S3). Key clinical predictors of increased initiation were total cholesterol >240 vs. <200 mg/dl (adjusted IPD 8.5 [95% CI, 8.1–8.9]); previous diabetes (7.2 [95% CI, 6.4–8.0]), previous coronary heart disease (5.1 [95% CI, 4.0–6.2]), and previous cerebrovascular disease (3.6 [95% CI, 2.3–4.9]). Decreased initiation was seen in the oldest age categories in this model that controlled for calendar time (comparing ages 75–79 yrs and 80+ yrs to 65–69 yrs, –1.5 [95% CI, –2.0– –1.0] and –2.4 [95% CI, –3.1– –1.8], respectively) (Appendix, Table S3).

3.2 Predictors before versus after incident coronary heart disease

In separate models representing primary and secondary prevention, respectively, there was increased initiation over calendar time for primary prevention but little change over time in initiation for secondary prevention; women with previous hypertension and diabetes, compared with those without disease, showed larger absolute increases in initiation in secondary prevention than in primary prevention (Table 3). Fewer multivitamin users and more current smokers initiated statins in settings of secondary prevention (non-use vs. 1+ days per month multivitamin use: RERI 0.715 [95% CI 0.255, 1.174], AP 0.308 [95% CI 0.150, 0.467], and SI 2.185 [95% CI 1.304, 3.661]; current smoker vs. current non-smoker: RERI 1.490 [95% CI 0.280, 2.700], AP 0.430 [95% CI 0.224, 0.637], and SI 2.533 [1.475, 4.349]) (Table 3). Decreased initiation was seen among younger (< 55 yrs) age groups compared with mid-range (60–74 yrs) groups in secondary prevention but not in primary prevention, though confidence intervals for the youngest age groups in the secondary prevention model were wide (Table 3).

3.3 Predictors during ATP-II versus ATP_III periods

In separate models representing ATP-II and ATP-III periods, higher total cholesterol predicted larger absolute increases in initiation in the ATP-III time period (total cholesterol 200+ vs. <200: RERI 2.148 [95% CI 1.505, 2.792], AP 0.162 [95% CI 0.120, 0.204], and SI 1.213 [95% CI 1.148, 1.281]); in contrast, higher total cholesterol predicted larger relative increases of initiation in the ATP-II (earlier) period (adjusted ORs for ATP-II and ATP-III periods, respectively, 4.1 [95% CI 3.5, 4.7] and 2.2 [95% CI 2.1, 2.3] for total cholesterol 200–239 vs. <200 mg/dl, and 14.2 [95% CI, 12.3–16.4] and 4.0 [95% CI, 3.7–4.3] for total cholesterol >240 vs. <200 mg/dl) (Appendix, Table S4). Women with previous diabetes, compared with those without, demonstrated larger absolute increase in initiation during ATP-III than ATP-II (Table 4). First incident coronary heart disease, cerebrovascular disease, diabetes, and hypertension occurring during the inter-questionnaire eligibility period were associated with markedly increased initiation overall with larger increases during ATP-III than ATP-II (Table 4), but the temporal order of disease incidence and initiation within the eligibility period was unknown. Stronger confounding was demonstrated on the multiplicative scale during ATP-II than ATP-III under a scenario of an observational study of statin initiation and cardiovascular disease outcomes confounded by total serum cholesterol (residual confounding bias, 15–20% and 8–11% for ATP-II and ATP-III, respectively) (Table 5).

Sensitivity analyses without eligibility period length restriction produced similar results overall, except that the peak in crude IR was later (2005–08) and attenuated (IR per 100 person-years 5.9 [95% CI, 5.8–6.1]).

4. DISCUSSION

4.1 Previous studies

Lo-Ciganic, et. al. (2013) reported an increase in prevalent statin use from 13% to 39% from 1997 to 2008 in a U.S. cohort of community dwelling individuals aged > 70 yrs at inception.

¹² The authors could not identify a change in the trend of prevalent use in association with

ATP-III guidelines, although the limited evidence on statin efficacy in older people during the time of their study may have influenced their results.^{37,38} The National Health and Nutrition Examination Survey showed prevalent statin use among women aged 45 yrs increasing from 2.6% in 1988–1994 to 23.6% in 2005–08.³⁹ Prevalent use approximately doubled from 1999–2002 to 2005–08 among both men and women aged 75 yrs³⁹ and from 1999–2002 to 2007–10 among type-II diabetics.¹⁴ Kildemoes, et. al. (2012) showed age-specific incidence of new use per 1,000 person-yrs (shown graphically) increasing from approximately 2–10 in 1999 to 50–75 in 2008 among ages 55–84, with sharply lower incidence among ages < 55 and ≥ 85 and increasingly larger proportions of new users comprised of asymptomatic individuals in the Danish Nationwide Cohort.¹¹ Teng, et. al. (2014) reported a spike in incidence of statin initiation in 2004 followed by flat incidence rates in a population-based time series analysis using Canadian claims data from 2003–2010.¹³ The decline in crude incidence of initiation after 2001–04 in the WHS cohort has not been evident in other studies or in our adjusted models. This absence could reflect a ‘depletion of susceptibles’ effect in this closed cohort followed over 20 years for a non-recurring event (first-time initiation). Women remaining in the analysis near the end of follow-up were, on average, more highly educated with greater exercise levels, increased vitamin use, decreased smoking, and decreased hypercholesterolemia compared with earlier in follow-up (Table 2). Regarding predictors, Danaei, et. al. (2011) showed that male sex, ages 60–75 yrs, greater LDL-cholesterol, diabetes, antihypertensive medication use, and more frequent medical encounters predicted new use of statins for primary prevention of coronary heart disease during 2000–2006 in the U.K.¹⁰ We found that hypertension, multivitamin non-use, later calendar time, current smoking, and diabetes predicted statin initiation more strongly in the secondary than primary prevention setting (Table 3), while greater total cholesterol, previous hypertension, coronary heart disease, and diabetes, and greater BMI predicted initiation more strongly during the ATP-III era than ATP-II (Table 4).

4.2 Implications for future research

Our findings have implications for confounding control in pharmacoepidemiologic studies of statin initiation. For example, in settings where total cholesterol is a weaker predictor of statin initiation, the overall confounding potential from lack of cholesterol data (e.g., an insurance claims analysis) may be reduced (Table 5). Furthermore, elevated total cholesterol predicted greater absolute increase of statin initiation after compared to before ATP-III (Table 4), but greater relative increase before ATP-III (Appendix, Table S4), owing to the very low incidence of initiation among women with normal cholesterol during ATP-II (Figure 2). Therefore, temporal changes of confounding potential by unmeasured cholesterol may be model scale-dependent.

4.3 Limitations

It was unknown when during the eligibility period an initiator began use, or whether a non-initiator may have started and stopped between questionnaires. Initiation without persistence to the next questionnaire was thus undetected and misclassified. Initiation occurring within the same eligibility period as first incidence of cardiovascular or other diseases was not classifiable with respect to predictor status. We parameterized these events separately to allow separate intercept estimations for those situations, thus improving sensitivity among

those classified as exposed versus unexposed. Incident coronary heart disease, cerebrovascular disease, and diabetes during the eligibility period were strongly associated with initiation. For coronary and cerebrovascular disease, it seems most likely that incident disease led to treatment; however, increased diabetes incidence has followed statin use in randomized trials.^{40,41} Also, rates and predictors of statin initiation in this selected group of female health professionals who volunteered for a long-term prevention trial and knew their cholesterol level may not be generalizable to all U.S. women. Finally, caution is warranted when interpreting parameter estimates from multivariable models as causal, as coefficients can represent different types of causal effects depending upon the covariate interrelationships.⁴²

4.4 Conclusions

The trends we observed in statin initiation over 20 years reflect an evolution from treatment largely targeted to those with hypercholesterolemia toward risk factor-associated treatment and increased initiation among women with diabetes and normal (<200 mg/dl) and borderline (200–239 mg/dl) total cholesterol.^{7,8} The role of serum cholesterol has changed over time, though the character of change was scale (multiplicative vs. additive) dependent. In pharmacoepidemiologic studies of statins, strength of confounding by important variables sometimes unmeasured in claims data, such as cholesterol level, may be calendar-time dependent.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

This study was supported by the following grants from the National Institutes of Health (United States): NIA R01/R56 AG023178, AG056479, NCI R01-CA047988, NHLBI R01-HL043851, NHLBI R01-HL080467, and NHLBI R01-HL099355. These sponsors had no role in the design of the study, in the collection, analysis, and interpretation of the data, in the writing of the report, or in the decision to submit the report for publication.

References

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344(8934):1383–1389. [PubMed: 7968073]
2. Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*. 1998;339(19):1349–1357. [PubMed: 9841303]
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*. 1996;335(14):1001–1009. [PubMed: 8801446]
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003;361(9364):1149–1158. [PubMed: 12686036]
5. Statins Waters D. and safety: applying the results of randomized trials to clinical practice. *Am J Cardiol*. 2003;92(6):692–695. [PubMed: 12972108]

6. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988;148(1):36–69. [PubMed: 3422148]
7. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269(23):3015–3023. [PubMed: 8501844]
8. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497. [PubMed: 11368702]
9. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421. [PubMed: 12485966]
10. Danaei G, Rodriguez LA, Canero OF, Logan R, Hernan MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22(1):70–96. [PubMed: 22016461]
11. Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy. 2012;108(2–3):216–227. [PubMed: 22975117]
12. Lo-Ciganic WH, Boudreau RM, Gray SL, et al. Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother. 2013;47(7–8):984–992. [PubMed: 23780807]
13. Teng JF, Gomes T, Camacho X, Grundy S, Juurlink DN, Mamdani MM. Impact of the JUPITER trial on statin prescribing for primary prevention. Pharmacotherapy. 2014;34(1):9–18. [PubMed: 23940007]
14. Wong HK, Ong KL, Cheung CL, Cheung BM. Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999–2010. Ann Epidemiol. 2014;24(7):516–521 e511. [PubMed: 24935464]
15. Li M, Ong KL, Tse HF, Cheung BM. Utilization of lipid lowering medications among adults in the United States 1999–2006. Atherosclerosis. 2010;208(2):456–460. [PubMed: 19700160]
16. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55. [PubMed: 15998890]
17. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):56–65. [PubMed: 15998891]
18. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–1304. [PubMed: 15753114]
19. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999;91(24):2102–2106. [PubMed: 10601381]
20. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women’s Health Study. J Womens Health Gend Based Med. 2000;9(1):19–27. [PubMed: 10718501]
21. Buring JE, Hennekens CH. The Women’s Health Study: summary of the study design. J Myocardial Ischemia. 1992;4(3):27–29.
22. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation. 2001;104(4):393–398. [PubMed: 11468199]
23. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1(6):466–473. [PubMed: 2090285]

24. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med.* 2015;175(4):531–539. [PubMed: 25686030]
25. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc.* 2000;32(9 Suppl):S498–504. [PubMed: 10993420]
26. U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. ODPHP Publication No U0036. 2008.
27. Huang PY, Buring JE, Ridker PM, Glynn RJ. Awareness, accuracy, and predictive validity of self-reported cholesterol in women. *J Gen Intern Med.* 2007;22(5):606–613. [PubMed: 17370032]
28. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 1997;20(7):1183–1197. [PubMed: 9203460]
29. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. *Epidemiology.* 2008;19(6):766–779. [PubMed: 18854702]
30. Hellevik O Linear versus logistic regression when the dependent variable is a dichotomy. *Quality & Quantity.* 2007;43(1):59–74.
31. Cheung YB. A modified least-squares regression approach to the estimation of risk difference. *Am J Epidemiol.* 2007;166(11):1337–1344. [PubMed: 18000021]
32. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. *Stat Med.* 1990;9(12):1501–1515. [PubMed: 2281238]
33. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. *Epidemiology.* 1992;3(5):452–456. [PubMed: 1391139]
34. Lundberg M, Fredlund P, Hallqvist J, Diderichsen F. A SAS program calculating three measures of interaction with confidence intervals. *Epidemiology.* 1996;7(6):655–656. [PubMed: 8899400]
35. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. *Epidemiology.* 2005;16(1):17–24. [PubMed: 15613941]
36. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation.* 1998;97(18):1837–1847. [PubMed: 9603539]
37. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. *Ann Intern Med.* 2010;152(8):488–496, W174. [PubMed: 20404379]
38. Pedro-Botet J, Climent E, Chillaron JJ, Toro R, Benaiges D, Flores-Le Roux JA. Statins for primary cardiovascular prevention in the elderly. *J Geriatr Cardiol.* 2015;12(4):431–438. [PubMed: 26345308]
39. National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD 2011.
40. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med.* 2008;359(21):2195–2207. [PubMed: 18997196]
41. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.* 2010;375(9716):735–742. [PubMed: 20167359]
42. Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. *Am J Epidemiol.* 2013;177(4):292–298. [PubMed: 23371353]

Key points:

1. We aimed to describe changing roles of predictors of statin initiation before and after incident coronary heart disease, and before and after publication of National Cholesterol Education Program Adult Treatment Panel-III (ATP-III) guidelines in a cohort of U.S. women initially free from cardiovascular disease.
2. Key predictors of initiation overall were self-reported total serum cholesterol, previous incident coronary heart disease, cerebrovascular disease, and diabetes , and calendar time.
3. Secular trends demonstrated increased initiation among diabetics and women with normal and borderline total cholesterol levels in later years.
4. The changing role of serum cholesterol level was scale (multiplicative vs. additive) dependent, with elevated total cholesterol predicting greater absolute increase of statin initiation after compared to before ATP-III, but greater relative increase before ATP-III.
5. In pharmacoepidemiologic studies of statins the strength of confounding by important variables sometimes unmeasured in claims data, such as cholesterol level, may be calendar time dependent.

Figure 1.

Flow diagram depicting the derivation of the study sample. A total of 34,382 women contributed 225,757 questionnaires to the analysis.

Figure 2.

Line graph showing trends of crude incidence rates of statin initiation over five 4-year time periods overall (solid black line) and by level of most recently reported total cholesterol level (dashed colored lines).

Table 1.

Eligibility criteria for enrollment into the Women’s Health Study

Aged 45 years
Post-menopausal or had no intention of becoming pregnant
No previous history cardiovascular disease, cancer (except non-melanoma skin cancer), or other major chronic illness
No history of serious side effect to any study treatments
Not taking aspirin, aspirin-containing medications, non-steroidal anti-inflammatories, Vitamins A or E, or beta-carotene more than once per week
Willingness to forgo use of aspirin or anti-inflammatories during the trial
Not taking anticoagulants or corticosteroids
Successful completion of a 3-month placebo run-in

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Covariate distributions among included women at selected survey times (number (%) of women)

		Questionnaire Year(s)				
		1993–95 [†]	2004 [‡]	2011 [§]		
All women	Number [¶]	30,427	20,092	13,231		
Age (yrs)	<50	9,843 (32)	-	-		
	50–54	8,693 (29)	-	-		
	55–59	5,482 (18)	6,392 (32)	-		
	60–64	3,417 (11)	5,956 (30)	2,697 (20)		
	65–69	2,051 (7)	3,764 (19)	4,688 (35)		
	70–74	733 (2)	2,148 (11)	2,975 (22)		
	75–79	171 (1)	1,294 (6)	1,609 (12)		
	80+	37 (0)	538 (3)	1,262 (10)		
Race	Other	1,523 (5)	862 (4)	524 (4)		
	White non-Hispanic	28,904 (95)	19,230 (96)	12,707 (96)		
Education	LVN/LPN	3,910 (13)	2,412 (12)	1,290 (10)		
	RN < 4-yr	13,169 (43)	8,913 (44)	5,387 (41)		
	Bachelors	7,144 (23)	4,816 (24)	3,442 (26)		
	Graduate	6,204 (20)	3,951 (20)	3,112 (24)		
Body mass index (kg/m²)	<25	15,750 (52)	9,328 (46)	6,583 (50)		
	25–30	9,339 (31)	6,533 (33)	4,186 (32)		
	>30	5,338 (18)	4,231 (21)	2,462 (19)		
Smoking	Never smoked	15,854 (52)	10,482 (52)	6,692 (51)		
	Past smoker	11,080 (36)	8,089 (40)	5,956 (45)		
	Current smoker	3,493 (11)	1,521 (8)	583 (4)		
Exercise (met-hours/week)	<7.5	13,926 (46)	8,143 (41)	4,423 (33)		
	7.5–21	9,385 (31)	6,194 (31)	3,939 (30)		
	>21	7,116 (23)	5,755 (29)	4,869 (37)		
Alcohol use	Rarely/Never	13,397 (44)	8,123 (40)	5,157 (39)		
	1–3 drinks/mo	4,059 (13)	2,400 (12)	1,269 (10)		
	1–6 drinks/wk	9,895 (33)	7,111 (35)	4,629 (35)		
	1+ drinks/day	3,076 (10)	2,458 (12)	2,176 (16)		
Multivitamin use	None	18,662 (61)	8,716 (43)	4,136 (31)		
	1–20 days/mo	4,067 (13)	1,580 (8)	1,290 (10)		
	>20 days/mo	7,698 (25)	9,796 (49)	7,805 (59)		
Menopausal status	Premenopausal	8,441 (28)	419 (2)	-		
	Uncertain/Unclear	5,617 (18)	1,089 (5)	-		
	Postmenopausal	16,369 (54)	18,584 (92)	13,231 (100)		
Hormone replacement therapy	Never	14,730 (48)	4,069 (20)	2,654 (20)		
	Former	2,624 (9)	9,525 (47)	9,010 (68)		
	Current	13,073 (43)	6,498 (32)	1,567 (12)		
Total cholesterol	<200	14,868 (49)	10,066 (50)	7,276 (55)		

		Questionnaire Year(s)					
		1993–95 [†]		2004 [‡]		2011 [§]	
(mg/dl, self-reported)	200–239	11,431	(38)	7,675	(38)	4,901	(37)
	240+	4,128	(14)	2,351	(12)	1,054	(8)
Previous disease event or diagnosis:							
	Coronary heart disease ^{††††}	122	(0)	440	(2)	294	(2)
	Cerebrovascular disease ^{††§§}	13	(0)	310	(2)	228	(2)
	Hypertension diagnosis ^{¶¶}	7,996	(26)	9,831	(49)	7,971	(60)
	Diabetes diagnosis ^{¶¶}	774	(3)	910	(5)	529	(4)
	Parental history myocardial infarction at age <60	4,399	(14)	2,642	(13)	1,576	(12)

Abbreviations: LPN, Licensed Practical Nurse; LVN, Licensed Vocational Nurse; RN, Registered Nurse

[†] Baseline covariate values among women contributing an observation from questionnaire administered 12 months post-randomization.

[‡] Updated covariate values among women contributing an observation from questionnaire administered at conclusion of randomized trial.

[§] Updated covariate values among women contributing an observation from 7th yearly post-trial observational follow-up questionnaire.

[¶] Number of women that were eligible to initiate and provided statin use data on the specified questionnaire.

^{††} Thirteen (13) women who enrolled into the study having reported no history of cardiovascular disease were later discovered to have had myocardial infarction, coronary revascularization, or stroke prior to enrollment by medical records review. The remaining cases of heart or cerebrovascular disease prior to randomization were either incident cases that occurred during the run-in period, or women discovered to have had angina or transient ischemic attack prior to enrollment.

^{‡‡} Confirmed myocardial infarction, coronary artery bypass graft, percutaneous angioplasty, or angina.

^{§§} Confirmed stroke, carotid endarterectomy, or transient ischemic attack.

^{¶¶} Self-reported physician diagnosis or use of antihypertensive or antidiabetic medications or insulin.

Table 3.

Selected adjusted initiation proportion (%) differences (95% CI)[†] for statin initiation by prior incident coronary heart disease[‡], Women's Health Study, 1993–2012

		Prior Incident Coronary Heart Disease[§]	
		No (Primary prevention)	Yes (Secondary prevention)
	Number initiations	10,508	377
	Number questionnaires	222,567	3,190
Age (yrs)	<50	0.2 (−0.2, 0.6)	−6.6 (−14.5, 1.2)
	50–54	0.1 (−0.2, 0.5)	−4.5 (−10.6, 1.6)
	55–59	0.0 (−0.3, 0.4)	−1.1 (−5.3, 3.0)
	60–64	0.0 (−0.3, 0.3)	−0.1 (−3.5, 3.3)
	65–69	0	0
	70–74	−0.4 (−0.8, 0.0)	−0.5 (−4.4, 3.4)
	75–79	−1.4 (−1.9, −0.9)	−3.6 (−7.7, 0.6)
	80+	−2.6 (−3.2, −2.0)	2.7 (−3.0, 8.4)
Body mass index (kg/m²)	<25	0	0
	25–30	1.0 (0.8, 1.2)	1.8 (−0.8, 4.5)
	>30	0.7 (0.5, 1.0)	1.2 (−1.8, 4.1)
Smoking	Never Smoked	0	0
	Past Smoker	0.2 (0.0, 0.4)	−0.5 (−2.8, 1.8)
	Current Smoker	0.5 (0.1, 0.8)	6.0 (1.1, 10.9)
Multivitamin use	None	0	0
	1–20 days/mo	−0.4 (−0.7, −0.1)	−5.3 (−8.9, −1.6)
	>20 days/mo	0.3 (0.1, 0.5)	−1.8 (−4.3, 0.6)
Total cholesterol (mg/dl, self-reported)	<200	0	0
	200–239	3.0 (2.9, 3.2)	4.2 (1.8, 6.7)
	240+	8.5 (8.1, 8.9)	8.0 (4.2, 11.8)
First incident cerebrovascular disease[¶]	Never ^{††}	0	0
	Previously ^{††}	3.6 (2.2, 5.0)	3.7 (−3.0, 10.4)
	During Eligibility Period ^{§§}	19.4 (15.7, 23.0)	12.7 (−11.1, 36.5)
First incident diabetes diagnosis	Never ^{††}	0	0
	Previously ^{††}	7.0 (6.3, 7.8)	11.9 (6.7, 17.0)
	During Eligibility Period ^{§§}	14.7 (12.3, 17.0)	28.7 (8.9, 48.5)
First incident hypertension diagnosis	Never ^{††}	0	0
	Previously ^{††}	2.3 (2.1, 2.5)	6.0 (3.6, 8.4)
	During Eligibility Period ^{§§}	3.4 (2.9, 3.9)	8.9 (2.6, 15.1)
Calendar year of questionnaire	1993–1996	0	0
	1997–2000	0.4 (0.2, 0.6)	−3.4 (−8.4, 1.7)
	2001–2004	3.2 (2.9, 3.5)	0.7 (−4.8, 6.2)
	2005–2008	4.4 (4.1, 4.6)	1.0 (−4.2, 6.3)

	Prior Incident Coronary Heart Disease [§]	
	No (Primary prevention)	Yes (Secondary prevention)
2009–2012	4.6 (4.3, 5.0)	–2.6 (–8.3, 3.0)

Abbreviations: CI, confidence interval

[†] Initiation proportion, expressed as percentage, estimated using linear regression models (binary outcome) with empirical variance estimation. The model included all variables shown on Table 2. Variables exhibiting interaction by incident heart disease or calendar time are shown.

[‡] Confirmed myocardial infarction, coronary artery bypass graft, percutaneous angioplasty, or angina.

[§] The key contributors to statistical interaction by prior incident coronary heart disease were incident hypertension, multivitamin use, calendar time, smoking, and incident diabetes (score tests for interaction term(s), $p=.006$, $.03$, $.03$, $.05$, and $.09$, respectively).

[¶] Confirmed stroke, carotid endarterectomy, or transient ischemic attack.

^{††} Statin initiation vs. non-initiation without first lifetime incidence before the questionnaire date on which use or non-use of statins was reported.

^{†††} Statin initiation vs. non-initiation with first lifetime incidence before the start of the eligibility period.

^{§§} Statin initiation vs. non-initiation without first lifetime incidence before the start of the eligibility period, but with first lifetime incidence during the eligibility period. For women who initiated in this category ($n=309$ for coronary heart disease), the temporal order of disease incidence and statin initiation is unknown.

Table 4.

Selected adjusted initiation proportion (%) differences (95% CI)[†] for statin initiation by calendar time period, Women's Health Study, 1993–2012

		Calendar Time Period [‡]	
		1993 – 05/15/2001 (ATP-II)	05/16/2001 – 2012 (ATP-III)
	Number initiations	2,094	8,791
	Number questionnaires	88,420	137,337
Age (yrs)	<50	−0.7 (−1.2, −0.2)	−
	50–54	−0.6 (−1.1, −0.1)	0.8 (−1.1, 2.6)
	55–59	−0.5 (−1.0, 0.0)	0.2 (−0.2, 0.7)
	60–64	−0.6 (−1.1, 0.0)	0.2 (−0.2, 0.5)
	65–69	0	0
	70–74	−0.4 (−1.2, 0.4)	−0.4 (−0.9, 0.1)
	75–79	−1.5 (−2.7, −0.4)	−1.5 (−2.1, −1.0)
	80+	−3.1 (−4.7, −1.5)	−2.4 (−3.1, −1.7)
Body mass index (kg/m²)	<25	0	0
	25–30	0.3 (0.1, 0.6)	1.5 (1.3, 1.8)
	>30	0.1 (−0.2, 0.4)	1.2 (0.9, 1.6)
Smoking	Never Smoked	0	0
	Past Smoker	0.1 (−0.1, 0.3)	0.2 (−0.1, 0.5)
	Current Smoker	0.6 (0.2, 1.0)	0.6 (0.0, 1.1)
Multivitamin use	None	0	0
	1–20 days/mo	−0.1 (−0.4, 0.2)	−0.8 (−1.2, −0.3)
	>20 days/mo	0.0 (−0.2, 0.3)	0.3 (0.1, 0.6)
Total cholesterol (mg/dl, self-reported)	<200	0	0
	200–239	1.6 (1.5, 1.8)	4.0 (3.8, 4.3)
	240+	7.5 (7.0, 8.0)	9.3 (8.7, 9.9)
First incident coronary heart disease[§]	Never [¶]	0	0
	Previously ^{††}	6.7 (4.4, 9.0)	4.7 (3.5, 6.0)
	During Eligibility Period ^{‡‡}	16.4 (12.5, 20.4)	50.2 (45.7, 54.7)
First incident cerebrovascular disease^{§§}	Never [¶]	0	0
	Previously ^{††}	4.3 (0.5, 8.1)	3.3 (1.9, 4.7)
	During Eligibility Period ^{‡‡}	6.1 (2.1, 10.2)	26.7 (21.7, 31.8)
First incident diabetes diagnosis	Never [¶]	0	0
	Previously ^{††}	3.1 (2.1, 4.0)	9.2 (8.2, 10.2)
	During Eligibility Period ^{‡‡}	4.2 (1.7, 6.8)	21.4 (18.0, 24.8)
First incident hypertension diagnosis	Never [¶]	0	0
	Previously ^{††}	1.6 (1.3, 1.8)	2.8 (2.6, 3.1)
	During Eligibility Period ^{‡‡}	1.7 (1.2, 2.3)	5.0 (4.2, 5.8)

Abbreviations: CI, confidence interval; ATP, Adult Treatment Panel

[†] Initiation proportion, expressed as percentage, estimated using linear regression models (binary outcome) with empirical variance estimation. The model included all variables shown on Table 2. Variables exhibiting interaction by incident heart disease or calendar time are shown.

[‡] May 15, 2001 corresponds to the publication date of Adult Treatment Panel III Cholesterol Treatment Guidelines. There were no observations for which the eligibility period crossed over May 15, 2001 with restriction of eligibility period length to < 27 mo due to the coincidence of a 5-year period without query of statin use in the survey design. The strongest contributors to statistical interaction by time period were total cholesterol, incident diabetes, coronary heart disease, and hypertension, and BMI (score tests for interaction, all $p < .0001$).

[§] Confirmed myocardial infarction, coronary artery bypass graft, percutaneous angioplasty, or angina.

[¶] Statin initiation vs. non-initiation without first lifetime incidence before the questionnaire date on which use or non-use of statins was reported.

^{††} Statin initiation vs. non-initiation with first lifetime incidence before the start of the eligibility period.

^{‡‡} Statin initiation vs. non-initiation without first lifetime incidence before the start of the eligibility period, but with first lifetime incidence during the eligibility period. For women who initiated in this category, the temporal order of disease incidence and statin initiation is unknown.

^{§§} Confirmed stroke, carotid endarterectomy, or transient ischemic attack.

Table 5.

Estimation of residual confounding bias for unmeasured total serum cholesterol during ATP-II and ATP-III periods

	Time period	
	1993 – 05/15/2001 (ATP-II)	05/16/2001 – 2012 (ATP-III)
Observed odds ratio [†]	7.71	2.35
Relative risk of incident cardiovascular disease by total serum cholesterol (mg/dl): [‡]		
200–239 vs. <200	1.51	1.51
240+ vs. <200	1.72	1.72
Residual confounding bias (%) by total serum cholesterol (mg/dl): [§]		
200–239 vs. <200	15%	8%
240+ vs. <200	20%	11%

Abbreviations: ATP, Adult Treatment Panel

[†] Calculated from 2x2 bivariate proportions of statin initiation vs. non-initiation and total cholesterol 200+ vs. <200 from the Women's Health Study

[‡] Literature-based relative risk of elevated total cholesterol on incident cardiovascular disease from the Framingham risk prediction model, adjusted for age, high density lipoprotein, blood pressure, smoking, and diabetes among middle-aged women (Wilson, et. al, 1998)³⁶

[§] Calculated using method described by Schneeweiss, et. al, 2005³⁵